FAK/PYK2 inhibitors defactinib and VS-4718 enhance immune checkpoint inhibitor efficacy

Documenti analoghi

• PYK2/FAK inhibitors reverse hypoxia-induced drug resistance in multiple myeloma
  di: Muz, Barbara, et al.
  Pubblicazione: (2019)
• Merlin deficiency predicts for FAK inhibitor sensitivity: A synthetic lethal relationship
  di: Shapiro, Irina M., et al.
  Pubblicazione: (2014)
• Targeting focal adhesion kinase reprograms the pancreatic tumor microenvironment and renders pancreas cancer responsive to checkpoint immunotherapy
  di: Jiang, Hong, et al.
  Pubblicazione: (2015)
• Initial Testing of VS-4718, a novel inhibitor of Focal Adhesion Kinase (FAK), against pediatric tumor models by the Pediatric Preclinical Testing Program
  di: Kurmasheva, Raushan T., et al.
  Pubblicazione: (2016)
• Tumor kinetics prior to treatment correlate with response to checkpoint inhibitors
  di: Cadena, Alexandra P, et al.
  Pubblicazione: (2015)